Advertisement

Hepatology International

, Volume 2, Issue 2, pp 190–195 | Cite as

Nonalcoholic fatty liver disease in a district general hospital: clinical presentation and risk factors

  • Wing-Kin SynEmail author
  • Peter Nightingale
  • Jeffrey M. Bateman
Original Article

Abstract

Introduction

Nonalcoholic fatty liver disease (NAFLD) affects one-fifth of the adult population and is currently the commonest liver problem in the western world. The prevalence of NAFLD is likely to rise over the coming decades in parallel to the obesity and diabetes epidemics. A retrospective study was undertaken in a UK. district general hospital (DGH) to determine the clinical and laboratory features of patients with NAFLD.

Methods and findings

A total of 48 patients with NAFLD were identified. Most (54%) were asymptomatic on presentation and 90% had an echogenic liver on ultrasonography (USS). Liver tests were elevated in the majority, but did not distinguish between simple steatosis and steatohepatitis. Having features of the metabolic syndrome and a low platelet count (P = 0.028) may help identify patients with advanced hepatic fibrosis.

Conclusions

NAFLD is common in the DGH and should be considered in all patients with metabolic risk factors. A liver biopsy should be considered in those with low platelets, type II diabetes mellitus, and the metabolic syndrome.

Keywords

District general hospital Liver tests Metabolic syndrome Nonalcoholic fatty liver Ultrasonography 

Abbreviations

NASH

(Nonalcoholic) steatohepatitis

USS

Ultrasound

WCC

White cell count

INR

International normalized ratio

ALT

Alanine aminotransferase

ALP

Alkaline phosphatase

GGT

Gamma gluteryltransferase

AST

Aspartate aminotransferase

BMI

Body mass index

ATP

Adult treatment panel

References

  1. 1.
    Ludwig J, Viggiano TR, McGill DB, Oh BJ. Nonalcoholic steatohepatitis: mayo clinic experiences with a hitherto unnamed disease. Mayo Clin Proc. 1980;55:434–8.PubMedGoogle Scholar
  2. 2.
    Chitturi S, Farrell GC. Etiopathogenesis of nonalcoholic steatohepatitis. Semin Liver Dis. 2001;21:27–41.PubMedCrossRefGoogle Scholar
  3. 3.
    Powell EE, Cooksley WG, Hanson R, et al. The natural history of non-alcoholic steatohepatitis: a follow-up study of 42 patients for up to 21 years. Hepatology. 1990;11:74–80.PubMedCrossRefGoogle Scholar
  4. 4.
    Bacon BR, Farahvash MJ, Janney CG, Neuschwander-tetri BA. Non-alcoholic steatohepatitis: an expanded clinical entity. Gastroenterology. 1994;107:1103–9.PubMedGoogle Scholar
  5. 5.
    Bianchi L. Liver biopsy in elevated liver function tests? An old question revisited. J Hepatol. 2001;35:290–4.PubMedCrossRefGoogle Scholar
  6. 6.
    Saadeh S, Younossi ZM, Remer EM, et al. The utility of radiological imaging in non-alcoholic fatty liver disease. Gastroenterology. 2002;123:745–50.PubMedCrossRefGoogle Scholar
  7. 7.
    Mofrad P, Contos M, Haque M, et al. Clinical and histologic spectrum of non-alcoholic fatty liver disease with normal ALT values. Hepatology. 2003;37:1286–92.PubMedCrossRefGoogle Scholar
  8. 8.
    Clark JM, Diehl AM. Defining non-alcoholic fatty liver disease: implications of epidemiological studies. Gastroenterology. 2003;124:248–50.PubMedCrossRefGoogle Scholar
  9. 9.
    Yu AS, Keefe EB. Elevated AST or ALT to non-alcoholic fatty liver disease: accurate predictor of disease prevalence? Am J Gastroenterol. 2003;98:955–6.PubMedCrossRefGoogle Scholar
  10. 10.
    Clark JM, Diehl AM. Non-alcoholic fatty liver disease: an underrecognized cause of cryptogenic cirrhosis. JAMA. 2003;289(22):3000–4.PubMedCrossRefGoogle Scholar
  11. 11.
    Schwimmer JB, Deutsch R, Behling C, et al. Fatty liver as a determinant of atherosclerosis. Hepatology. 2005;42:610A.CrossRefGoogle Scholar
  12. 12.
    George J, Farrell GC. Management of NASH: current and future perspectives on treatment. In: Farrell G, George J, de la Hall PM, McCullough AJ, editors. Fatty liver disease: NASH and related disorders. Malden: Blackwell Publishing; 2005. p. 194–207.Google Scholar
  13. 13.
    Office for National Statistics. Obesity among adults: by sex and NS-SeC. Social Trends 2001;34.Google Scholar
  14. 14.
    Livingstone MB. Childhood obesity in Europe: a growing concern. Public Health Nutr. 2001;4(1A):109–16.PubMedCrossRefGoogle Scholar
  15. 15.
    Lipscombe LL, Hux JE. Trends in diabetes prevalence, incidence, and mortality in Ontario, Canada 1995–2005: a population-based study. Lancet. 2007;369(9563):750–6.PubMedCrossRefGoogle Scholar
  16. 16.
    Ehtisham S, Barrett TG. The emergence of type 2 diabetes in childhood. Ann Clin Biochem. 2004;41(Pt 1):10–6.PubMedCrossRefGoogle Scholar
  17. 17.
    Ricci C, Longo R, Gioulis E, et al. Noninvasive in vivo quantitative assessment of fat content in human liver. J Hepatol. 1997;27(1):108–13.PubMedCrossRefGoogle Scholar
  18. 18.
    Siegelman ES, Rosen MA. Imaging of hepatic steatosis. Semin Liver Dis. 2001;21(1):71–80.PubMedCrossRefGoogle Scholar
  19. 19.
    Neuschwander-Tetri BA, Caldwell SH. Non-alcoholic steatohepatitis: summary of an AASLD Single Topic Conference. Hepatology. 2003;37:1202–19.PubMedCrossRefGoogle Scholar
  20. 20.
    Brunt EM, Janney CG, Di Bisceglie AM, Neuschwander-Tetri BA, Bacon BR. Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions. Am J Gastroenterol. 1999;94:2467–74.PubMedCrossRefGoogle Scholar
  21. 21.
    Expert Panel on Detection Evaluation and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). J Am Med Assoc. 2001;285:2486–97.CrossRefGoogle Scholar
  22. 22.
    Cua IH, George J. Non-alcoholic fatty liver disease. Hosp Med. 2005;66(2): 106–11.PubMedGoogle Scholar
  23. 23.
    George J, Farrell GC. Practical approach to the diagnosis and management of people with fatty liver diseases. In: Farrell G, George J, de la Hall PM, McCullough AJ, editors. Fatty liver disease: NASH and related disorders. Oxford: Blackwell Publishing; 2005. p. 181–93.Google Scholar
  24. 24.
    Marchesini G, Bugianesi E, Forlani G, et al. Non-alcoholic fatty liver, steatohepatitis, and the metabolic syndrome. Hepatology. 2003;37:917–23.PubMedCrossRefGoogle Scholar
  25. 25.
    Matteoni CA, Younossi ZM, Gramlich T, Boparai N, Liu YC, McCullough AJ. Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. Gastroenterology. 1999;116:1413–9.PubMedCrossRefGoogle Scholar
  26. 26.
    Powell EE, Jonsson JR, Clouston AD. Steatosis: co-factor in other liver diseases. Hepatology. 2005;42(1):5–13.PubMedCrossRefGoogle Scholar
  27. 27.
    Donthamsetty S, Bhave VS, Mitra MS, Latendresse JR, Mehendale HM. Nonalcoholic fatty liver sensitizes rats to carbon tetrachloride hepatotoxicity. Hepatology. 2007;45(2):391–403.PubMedCrossRefGoogle Scholar
  28. 28.
    Bondini S, Younossi ZM. Non-alcoholic fatty liver disease and hepatitis C infection. Minerva Gastroenterol Dietol. 2006;52(2):135–43.PubMedGoogle Scholar
  29. 29.
    Donthamsetty S, Bhave VS, Mitra MS, et al. Non alcoholic steatohepatitis (NASH) sensitizes liver to hepatotoxicity. Hepatology. 2005;42:631A.Google Scholar
  30. 30.
    Kon K, Ikejima K, Okumura K, et al. Acetaminophen induces severe liver injury in obese and diabetic KK-Ay mice. Hepatology. 2005;42:512A.CrossRefGoogle Scholar
  31. 31.
    Kessler A, Levy Y, Roth A, et al. Increased prevalence of NAFLD in patients with acute myocardial infarction independent of BMI. Hepatology. 2005;42:623A.Google Scholar
  32. 32.
    Clark JM, Brancati FL, Diehl AM. The prevalence and etiology of elevated aminotransferase levels in the United States. Am J Gastroenterol. 2003;98(5):960–7.PubMedCrossRefGoogle Scholar
  33. 33.
    Prati D, Taioli E, Zanella A, et al. Updated definitions of health ranges for serum amino transferase levels. Ann Intern Med. 2002;137:1–9.PubMedGoogle Scholar
  34. 34.
    Graif M, Yanuka M, Baraz M. Quantitative estimation of attenuation in ultrasound video images: correlation with histology in diffuse liver disease. Invest Radiol. 2000;35:319–24.PubMedCrossRefGoogle Scholar
  35. 35.
    Joseph A, Saverymuttu S, Al-Sam S, et al. Comparison of liver histology with ultrasonography in assessing diffuse parenchymal liver disease. Clin Radiol. 1991;43:26–31.PubMedCrossRefGoogle Scholar
  36. 36.
    Marrero JA, Fontana RJ, Fu S, et al. Alcohol, tobacco and obesity are synergistic risk factors for hepatocellular carcinoma. J Hepatol. 2005;42:218–24.PubMedCrossRefGoogle Scholar
  37. 37.
    Hashimoto E, Yatsuji S, Kaneda H, et al. The characteristics and natural history of Japanese patients with nonalcoholic fatty liver disease. Hepatol Res. 2005;33:72–6.PubMedCrossRefGoogle Scholar
  38. 38.
    Pinto HC, Baptista A, Camilo ME, et al. Non-alcoholic steatohepatitis: clinicopathological comparison with alcoholic hepatitis in ambulatory and hospitalized patients. Dig Dis Sci. 1996;41:172–9.PubMedCrossRefGoogle Scholar
  39. 39.
    Angulo P, Keach JC, Batts KP, Lindor KD. Independent predictors of liver fibrosis in patients with non-alcoholic steatohepatitis. Hepatology. 1999;30:1356–62.PubMedCrossRefGoogle Scholar
  40. 40.
    Ratziu V, Giral P, Charlotte F, et al. Liver fibrosis in overweight patients. Gastroenterology. 2000;118:1117–23.PubMedCrossRefGoogle Scholar
  41. 41.
    Clark JM. The epidemiology of nonalcoholic fatty liver disease in adults. J Clin Gastroenterol. 2006;40(3 Suppl 1):S5–10.PubMedGoogle Scholar
  42. 42.
    Medina J, Fernandez-Salazar LI, Garcia-Buey L, et al. Approach to the pathogenesis and treatment of nonalcoholic steatohepatitis. Diabetes Care. 2004;27:2057–66.PubMedCrossRefGoogle Scholar
  43. 43.
    Targher G, Bertolini L, Padovani R, et al. Prevalence of nonalcoholic fatty liver disease and its association with cardiovascular disease among type 2 diabetic patients. Diabetes Care. 2007;30(5):1212–8. [Epub 2007 Feb 2].Google Scholar
  44. 44.
    DelGaudio A, Boschi L, DelGaudio GA, Mastrangel L, Munars D. Liver damage in obese patients. Obes Surg. 2001;11:254–7.CrossRefGoogle Scholar
  45. 45.
    Silverman EM, Sapala JA, Appelman HD. Regression of hepatic steatosis in morbidly obese persons after gastric bypass. Am J Clin Pathol. 1995;104:23–31.PubMedGoogle Scholar
  46. 46.
    Klain J, Fraser D, Goldstein J, et al. Liver histology in the morbidly obese. Hepatology. 1989;10:873–6.PubMedCrossRefGoogle Scholar

Copyright information

© Asian Pacific Association for the Study of the Liver 2008

Authors and Affiliations

  • Wing-Kin Syn
    • 1
    • 2
    Email author
  • Peter Nightingale
    • 3
  • Jeffrey M. Bateman
    • 1
  1. 1.Princess Royal HospitalShropshireUK
  2. 2.Liver Unit and Hepatobiliary UnitQueen Elizabeth HospitalBirminghamUK
  3. 3.Wellcome Trust Clinical Research FacilityBirminghamUK

Personalised recommendations